mAb Development

Feb 14, 2017
Evaluate and BioPharm International highlight the antibody-based therapeutics that may have 2017 launch dates in the United States.
Feb 13, 2017
EvaluatePharma and BioPharm International highlight the antibody-based therapeutics that may gain United States Regulatory approval in 2017.
Feb 03, 2017
According to results from the FOURIER trial, Repatha significantly reduced the risk of cardiovascular events and death in patients with atherosclerotic cardiovascular disease.
Jan 09, 2017
The companies will combine expertise on T-cell therapies with two or more binding domains to create novel oncology medications.
Nov 01, 2016
BioPharm International
The development of mAb formulations poses challenges at the manufacturing, stability, analytical, and administration levels.
Oct 06, 2016
By BioPharm International Editors
The companies are collaborating on the commercialization of two biosimilar candidates in the US and Canada.
Oct 06, 2016
Results from the Phase III POLLUX trial with Janssen’s Darzalex showed that the drug was effective at reducing disease progression in patients with relapsed or refractory multiple myeloma.
Oct 03, 2016
By BioPharm International Editors
Allergan entered into a licensing agreement with AstraZeneca for MEDI2070, an anti-IL-23 monoclonal antibody in phase IIB development for the treatment of patients with moderate-to-severe Crohn’s disease.
Oct 01, 2016
BioPharm International
An approach to stabilize PBS-based formulations could provide a simple physiological solution for use of proteins in research, preclinical, diagnostics, and clinical studies, as well as commercial biotherapeutic products.
Sep 01, 2016
BioPharm International
This study offers a strategy for stabilization of biotherapeutics for long-term frozen storage in PBS-based formulations.
lorem ipsum